Vertex Pharmaceuticals Incorporated (VRTX) Receives Hold Rating from Maxim Group

Vertex Pharma

Vertex Pharma

"The company's diluted EPS for trailing twelve months was 1.03". Northwestern Mutual Investment Management Company LLC's holdings in Vertex Pharmaceuticals were worth $812,000 as of its most recent filing with the SEC.

Institutional ownership refers to the ownership stake in a company that is held by large financial organizations, pension funds or endowments.

Needham Company LLC raised the target price of Vertex Pharmaceuticals (NDAQ:VRTX) to $155.00 reporting a possible upside of 0.16%. Achmea Investment Management B.V. boosted its holdings in Vertex Pharmaceuticals by 68.0% in the second quarter. Jennison Associates LLC now owns 5,055,122 shares of the pharmaceutical company's stock valued at $651,454,000 after buying an additional 3,626,368 shares during the period. RNC Capital Management LLC now owns 2,978 shares of the pharmaceutical company's stock valued at $384,000 after acquiring an additional 150 shares in the last quarter. (TSRO) stock showed the move of -1.36% with the closing price of $118.68. Axa holds 0.17% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 502,788 shares. Hedge funds and other institutional investors own 92.88% of the company's stock. The company's 50 day moving average price is $79.94 and its 200 day moving average price is $87.05. The firm has a market capitalization of $39.79 billion, a PE ratio of 151.59 and a beta of 1.75. Vertex Pharmaceuticals Incorporated has a 12-month low of $71.46 and a 12-month high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.33. Revenue during the quarter was $317.45 million, representing 6% growth from $300.13 million in year-ago quarter. Vertex Pharmaceuticals had a return on equity of 4.64% and a net margin of 12.05%.

Quarterly Revenue Growth on year-over-year basis stands at 26.1 percent. During the same period in the prior year, the firm earned $0.24 EPS. On average, analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 earnings per share for the current fiscal year.

Yesterday Vertex Pharmaceuticals (NDAQ:VRTX) traded -0.36% lower at $133.50. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & global trademark & copyright legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/12/westpac-banking-corp-sells-17855-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html. The stock was sold at an average price of $129.85, for a total value of $74,404.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

By seeing technical data of Redfin Corporation (NASDAQ:RDFN) and Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), some interesting facts appear regarding these companies. The shares were sold at an average price of $90.98, for a total value of $460,540.76. Following the completion of the transaction, the senior vice president now directly owns 22,648 shares in the company, valued at $3,020,337.28. The disclosure for this sale can be found here. The insider Chodakewitz Jeffrey sold 8,021 shares worth $914,394.

A number of other research analysts also recently issued reports on VRTX. Maxim Group maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Wednesday, July 19 with "Buy" rating. BMO Capital Markets maintained the stock with "Buy" rating in Tuesday, July 18 report. Finally, Cowen and Company reiterated a "buy" rating on shares of Vertex Pharmaceuticals in a research note on Tuesday, August 1st. Analysts set a 12-month price target of $58.13 a share. Finally, J P Morgan Chase & Co set a $175.00 target price on shares of Vertex Pharmaceuticals and gave the stock a "buy" rating in a report on Wednesday, July 19th. Six equities research analysts have rated the stock with a hold rating and twenty-two have issued a buy rating to the company's stock. The stock presently has an average rating of "Buy" and a consensus price target of $162.88.

Switzerland-based Credit Suisse Ag has invested 0.05% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Notícias recomendadas

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.